Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics, Inc. (symbol: CATX) is a cutting-edge medical technology and radiopharmaceutical company focused on pioneering innovative cancer treatments. The company has developed a proprietary technology that uses the alpha-emitting isotope 212Pb to target and destroy cancer cells with precision, minimizing damage to surrounding healthy tissues. This breakthrough technology is designed to deliver potent radiation directly to cancer cells via specialized targeting peptides, offering a promising alternative to traditional cancer treatments.
One of Perspective Therapeutics' most notable advancements is the introduction of cesium-131 for brachytherapy, a form of cancer treatment that involves implanting radioactive seeds directly into the cancerous tissue. This method, initially theorized in the 1960s but only recently made feasible by advancements in science and technology, provides a highly effective treatment for prostate cancer and other types of tumors. The company has invested millions of dollars and decades of research to bring this groundbreaking treatment to top medical centers, hospitals, and clinics across the United States.
Perspective Therapeutics is not only focused on improving existing cancer therapies but also actively participates in regulatory programs to advance their pipeline of innovative treatments. For instance, the company has engaged in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, as announced in the Federal Register. This program aims to ensure that their manufacturing processes meet the highest standards of quality and readiness for clinical application.
The company's financial condition remains robust, supported by strategic partnerships and ongoing research and development efforts. With a commitment to advancing cancer care, Perspective Therapeutics continues to explore new applications for their technologies, aiming to improve patient outcomes and expand their product offerings.
For investors and stakeholders, keeping an eye on Perspective Therapeutics' latest developments and financial performance is crucial. The company's innovative approach to cancer treatment and continuous efforts in research and development make it a significant player in the medical technology and radiopharmaceutical industry.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical development company focused on advanced cancer treatments, has announced its participation in two major investor conferences in March 2025.
The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, from 11:10 AM to 11:40 AM ET. Additionally, they will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference in Miami on March 11, 2025, from 3:30 PM to 3:55 PM ET.
Both events will be accessible via webcast, with replays available for 90 days through the Investors page on Perspective's website.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical development company focused on advanced cancer treatments, announced it will release its full year 2024 financial results and provide a business update on March 26, 2025, after market close. The financial report and business update will be accessible through the company's website newsroom section.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on advanced cancer treatments, has announced its participation in two major investor conferences in February 2025.
The company will attend Oppenheimer's 35th Annual Healthcare Life Sciences Conference, featuring a virtual fireside chat on Wednesday, February 12, 2025, from 2:00 p.m. to 2:30 p.m. ET. Additionally, they will participate in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York, NY on Friday, February 28, 2025.
Senior leadership team members will be available for one-on-one meetings with investors at both events. Webcasts will be accessible live and archived for 90 days through the Investors page on Perspective's website.
Perspective Therapeutics (NYSE: CATX) presented updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2025 ASCO Gastrointestinal Cancers Symposium. The trial focuses on patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors.
Key findings from nine patients in Cohorts 1 (2.5 mCi) and 2 (5.0 mCi) show: no dose-limiting toxicities, favorable safety profile, and promising efficacy. Three of seven patients in Cohort 2 experienced objective responses, with one confirmed response lasting 17 weeks. Five patients maintain stable disease.
The Safety Monitoring Committee supported proceeding with Cohort 3 dose escalation and expanding Cohort 2 enrollment. As of December 31, 2024, 18 patients have been dosed in Cohort 2. The company awaits FDA alignment before proceeding with Cohort 3.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated interim results from their Phase 1/2a trial of [212Pb]VMT-α-NET will be presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025, in San Francisco. The presentation, titled 'Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs),' will be featured in Poster Session B.
The company will host a webcast conference call on January 24, 2025, at 8:00 am ET to discuss the presented data. Dr. Richard L. Wahl, lead investigator and Professor of Radiology at Washington University School of Medicine, will participate alongside the management team. The initial results were previously presented with data cut-off on October 31, 2024.
Perspective Therapeutics (NYSE AMERICAN: CATX) has provided strategic updates and priorities for the next 12-18 months. The company reported preliminary unaudited cash and equivalents of $227.8M as of December 31, 2024, expected to fund operations into late 2026.
The company is advancing three clinical programs: VMT-α-NET for neuroendocrine tumors, which has shown promising safety data and clinical activity in 18 patients; VMT01 for melanoma treatment, demonstrating favorable safety profile and some clinical responses; and PSV359, a new asset targeting FAP-α in solid tumors, with potential enrollment starting mid-2025.
Additionally, four new assets are being evaluated for IND development. The company is expanding its manufacturing capabilities through improving existing facilities and developing recently acquired sites.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced its participation in two major healthcare conferences in San Francisco.
CEO Thijs Spoor will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, from 3:45 p.m. to 4:25 p.m. PT at The Westin St. Francis Hotel's Elizabethan B room. Additionally, the company will present at the Biotech Showcase conference on Tuesday, January 14, 2025, at 1:30 p.m. PT, taking place at the Hilton San Francisco - Union Square's Yosemite A Ballroom.
The management team will be available for one-on-one meetings with investors and strategic partners at both conferences, with interested parties directed to contact events@perspectivetherapeutics.com for scheduling.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Juan Graham as its new Chief Financial Officer (CFO) effective January 6, 2025. Jonathan Hunt, the former CFO, will transition to the role of Chief Accounting Officer (CAO). The company's CEO, Thijs Spoor, emphasized the strategic importance of this change as Perspective advances its radiopharmaceutical technology platform and builds manufacturing infrastructure.
Mr. Graham brings nearly 25 years of global experience in life sciences, having previously served as CFO at FibroGen, where he led global finance, capital formation, and strategic initiatives. Before that, he held various finance and business development roles at Johnson & Johnson. Mr. Graham holds an MBA from McGill University and a bachelor's degree from Tec de Monterrey.
Perspective Therapeutics has delivered initial clinical data for two new potential medicines and plans to advance further clinical programs and new initiatives under Mr. Graham's financial leadership.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on cancer treatments, has announced its participation in two major investor conferences in December 2024. The company's senior leadership will be available for one-on-one meetings with investors at both events.
The first appearance will be at the 36th Annual Piper Healthcare Conference in New York on December 3, featuring a fireside chat from 10:00-10:25 AM ET. The second event is the 7th Annual Evercore HealthCONx in Coral Gables, FL on December 5, with a fireside chat scheduled for 10:50-11:10 AM ET. Both events will be webcasted and available for replay for 90 days through the company's investor website.
Perspective Therapeutics announced initial results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the 2024 NANETS Symposium. The trial showed favorable safety profile with no dose-limiting toxicities at tested doses (2.5 and 5.0 mCi). Eight of nine patients achieved durable disease control, with six showing measurable tumor volume reduction. One patient achieved confirmed response per RECIST v1.1. The Safety Monitoring Committee recommended proceeding with dose escalation and expanding patient enrollment at 5.0 mCi. The company plans to consult with FDA for Cohort 3 initiation.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
What is Perspective Therapeutics, Inc.?
What is cesium-131 brachytherapy?
How does Perspective Therapeutics use the isotope 212Pb?
What are some recent achievements of Perspective Therapeutics?
Where can I find the latest news about Perspective Therapeutics?
What is brachytherapy?
Is Perspective Therapeutics a publicly traded company?
What types of cancer can be treated with Perspective Therapeutics' technology?
How does the company's financial condition support its research and development?
What is the significance of the Federal Register program mentioned?
